

GlaxoSmithKline (UK Ltd) and Betsi Cadwaladr University Health Board Executive Summary

Aligning to All-Wales COPD Management and Prescribing guideline post COVID

This summary has been written by GSK with consultation and approval from the Joint Working Project Team. Betsi Cadwaladr University Health Board and GSK are undertaking a Joint Working project with the aim of Aligning to All-Wales COPD Management and Prescribing guideline post COVID. This involves a balance of contributions from both parties with the pooling of skills, experience and resources: as part of this Interface Clinical Services Limited are subcontracted by GSK to provide required services. The project will run from August 2021- June 2022.

Key Objectives:

- Addressing unmet need in primary care by reviewing at risk COPD patients and implementing national COPD guideline
- Aligning pharmacological COPD management to national guidelines and to national decarbonisation strategy (where clinically appropriate)

Intended Benefits:

Patients	<ul style="list-style-type: none"> • Full review in line with national guidelines based on current therapy and risk stratification (patients may have not received a review otherwise or will receive quicker than when reviewed in yearly cycle) potentially increasing volume of those receiving a review, potentially leading to better outcomes • Optimisation of both non-pharmacological & pharmacological management • Fewer COPD- related interventions, including hospital admissions • Better informed about COPD management and treatment options • COPD managed in accordance with current best practice clinical guidance • Better experience of the healthcare system – access to an Interface Clinical Service Clinical pharmacist and/or upskilled primary care clinician at their own GP practice
NHS	<ul style="list-style-type: none"> • Realisation of value-based healthcare objectives of improved patient outcomes with reduced Costs. • Support with risk stratification • Additional resource support • Guideline implementation resulting in consistent prescribing and non-prescribing recommendations and promoting for sustainability • Possible achievement or move towards achieving of carbon reduction targets in line with national DPI:MDI prescribing ratio • Insight into COPD population at practice and local healthcare economy level to allow benchmarking and evaluation of care provision to support clinical governance and support equity of care • Opportunity to upskill primary care doctors and nurses • Better health outcomes for the COPD patient population • Reduction in COPD- related interventions, including hospital admissions
GSK	<ul style="list-style-type: none"> • Broadening of customer network • Demonstrate partnership working • Increase prescribing of DPI class (of which GSK have the Ellipta portfolio) in line with national DPI:MDI prescribing aspiration • Expansion of the COPD patient population who are managed according to current clinical and best practice guidelines as a result of the programme • Increase in the appropriate use of medicines licensed for COPD aligned to local or national guidance, will likely increase in the prescribing of GSK products as well as those of other pharmaceutical companies. • Better understanding of the challenges faced by the NHS in delivering high-quality patient services and care • Helps GSK to live its value of being a patient focussed company.